Product Description
AG013 is made up of genetically modified (GM) bacteria called Lactococcus lactis (L. lactis).
Mechanisms of Action: Angiogenesis Inhibitor, VEGFR Inhibitor
Novel Mechanism: No
Modality: Nondrug
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Oragenics
Company Location: Eastern America
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Mucositis|Head and Neck Cancer|Stomatitis|Non-Small-Cell Lung Cancer|Colorectal Cancer
Phase 1: Head and Neck Cancer|Mucositis|Stomatitis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00938080 |
AG013-ODOM-101 | P1 |
Completed |
Mucositis|Stomatitis|Head and Neck Cancer |
2012-09-01 |
2019-03-18 |
Treatments |
|
2016-004161-68 |
2016-004161-68 | P2 |
Completed |
Mucositis|Head and Neck Cancer |
2020-07-02 |
2025-06-29 |
Treatments |
|
NCT03234465 |
AG013-ODOM-201 | P2 |
Terminated |
Stomatitis|Mucositis |
2020-03-31 |
2020-10-06 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
2014-003811-13 |
SENSOR | P2 |
Completed |
Colorectal Cancer|Non-Small-Cell Lung Cancer |
2019-03-19 |
2025-07-02 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
07/10/2020 |
News Article |
Oragenics Provides Update on SARS-CoV-2 (COVID-19) Program |
|
04/15/2020 |
News Article |
Oragenics, Inc. Announces Early Top-Line Results of Phase 2 Clinical Trial of AG013 for Oral Mucositis in Chemoradiation Treatment of Head and Neck Cancer |
|
12/02/2019 |
News Article |
Oragenics, Inc. Announces Completion of Enrollment of Its Phase 2 Clinical Trial for AG013 in Oral Mucositis |
|
10/22/2019 |
News Article |
Oragenics, Inc. to Present at the BIO Investor Forum |